Moderna Stock Down 39% in Three Months: Buy the Dip or Wait?

Despite being a pioneer in developing one of the first and most widely used COVID-19 vaccines, shares of Moderna (MRNA) have been sliding down over the past few years due to waning demand for the vaccine.In the past three months, MRNA stock has lost nearly 40%, significantly underperforming the industry’s 17.1% decline, as seen in the chart below. While the company’s pipeline progress has been encouraging, the update to its business outlook for the next four years and a curtailed R&D budget did not sit well ...